SOUTH SAN FRANCISCO, Calif., June 14, 2018 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq:CTMX) a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced the appointment of Lloyd A. Rowland, Jr. as senior vice president, general counsel.
“Lloyd joins CytomX at a pivotal time as our deep clinical pipeline matures and we remain highly focused on bringing potentially transformative therapies to patients,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. “Given his broad experience with clinical and commercial-stage organizations, we could not be more pleased to have him join the CytomX team.”
Mr. Rowland brings to CytomX 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience. Most recently, Mr. Rowland held the position of senior vice president, general counsel and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to this, Mr. Rowland, over a twelve-year career at Amylin Pharmaceuticals, held various roles, most recently as vice president and chief compliance officer and formerly, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes cancer immunotherapies against clinically-validated targets, such as CX-072, a PD-L1-targeting Probody therapeutic wholly-owned by CytomX, BMS-986249, a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb and CX-188, a PD-1-targeting Probody therapeutic wholly-owned by CytomX. The company is also developing first-in-class Probody drug conjugates against high potential targets, including CX-2009, a CD166-targeting Probody drug conjugate wholly-owned by CytomX, and CX-2029, a CD71-targeting Probody drug conjugate partnered with AbbVie. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to advancing the pipeline. The process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties. Additional applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading “Risk Factors” included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2018. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Investors and Media:
VP, Investor Relations and Corporate Communications